The Risks and Benefits of Immune Checkpoint Blockade in Anti-AChR Antibody-Seropositive Non-Small Cell Lung Cancer Patients

Background: Anti-programmed cell death 1 (PD-1) monoclonal antibodies (Abs) unleash an immune response to cancer. However, a disruption of the immune checkpoint function by blocking PD-1/PD-ligand 1(PD-L1) signaling may trigger myasthenia gravis (MG) as a life-threatening immune-related adverse even...

Descripción completa

Detalles Bibliográficos
Autores principales: Saruwatari, Koichi, Sato, Ryo, Nakane, Shunya, Sakata, Shinya, Takamatsu, Koutaro, Jodai, Takayuki, Mito, Remi, Horio, Yuko, Saeki, Sho, Tomita, Yusuke, Sakagami, Takuro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407108/
https://www.ncbi.nlm.nih.gov/pubmed/30682845
http://dx.doi.org/10.3390/cancers11020140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407108/
https://www.ncbi.nlm.nih.gov/pubmed/30682845
http://dx.doi.org/10.3390/cancers11020140

Ejemplares similares